Drugs / PTX-022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04520750 | Sep 2020 → Jun 2021 | pachyonychia congenita | Palvella Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTX-022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04520750 ↗ |